Pharmaceutical Manufacturing and Formulation

The contract involves the manufacture of sterile, USP-compliant Bupivacaine and Epinephrine Injection, encompassing the full production process from active pharmaceutical ingredient (API) sourcing to formulation, sterile filling, and comprehensive quality control testing. This subcontract, titled Pharmaceutical Manufacturing and Formulation, is solicited by the Department of Defense through the Medical Supply Chain Pharmacy Field Support Activity. The manufacturing activities are to be performed at the designated location in Fort Bragg, with the requirement to meet strict pharmaceutical standards to ensure product safety and efficacy. The solicitation was posted on May 18, 2026, with responses due by May 26, 2026, indicating a fast turnaround for subcontractor proposals. The contract falls under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. While specific details such as agency office address and point of contact are not provided, the contract is accessible through the Department of Defense’s procurement portal, emphasizing its federal oversight and importance in supplying critical sterile injectable medications for military or medical operational use.